Mounting Data Shows J&J Vaccine as Effective as Pfizer and Moderna - The New York Times - 0 views
-
During the summer months, the gaps — particularly between J.&J. and Pfizer — began to narrow. By now, all the vaccines seem to be performing about equally well against coronavirus infections; in fact, Johnson & Johnson appears to be holding up slightly better.
-
As of Jan. 22, the latest data available, unvaccinated people were 3.2 times as likely to become infected as those who received the single-dose Johnson & Johnson vaccine; they were 2.8 times as likely to become infected as those who received two doses of the Moderna vaccine and 2.4 times as likely as those with two doses of Pfizer-BioNTech. Overall, then, the Johnson & Johnson vaccine appeared to be somewhat more protective against infection than the two alternatives.
-
Dr. Corey said the results jibe with his experience in H.I.V. research with the adenovirus that forms the backbone of the Johnson & Johnson vaccine. “It has much longer durability than almost any other platform that we’ve ever worked with,” he said.
- ...6 more annotations...
-
Scientists are only beginning to guess why the vaccine’s profile is improving with the passing months.
-
Levels of antibodies skyrocket in the first few weeks after immunization, but then rapidly wane. The J.&J. vaccine may produce antibodies that decline more slowly than those produced by the other vaccines, some research suggests. Or those antibodies may become more sophisticated over time, through a biological phenomenon called affinity maturation.
-
Perhaps, some researchers suggest, the vaccine offered a more robust defense against the Omicron variant, responsible for the huge increase in infections over the past few months. And studies have shown that the vaccine trains other parts of the immune system at least as well as the other two vaccines.
-
“It is a shame that we don’t have more direct study of outcomes among people who received J.&J.,” she said. That is in part because fewer people got the vaccine than the mRNA vaccines, she said, but also “because we’re relying on other countries generating data.”
-
Still, the data so far suggest that two doses of the J.&J. vaccine had an effectiveness of about 75 percent against hospitalization with the Omicron variant, comparable to the protection from the Pfizer-BioNTech vaccine. The researchers presented the findings last month at the Conference on Retroviruses and Opportunistic Infections in Denver.
-
Although the trial looked only at people who got two doses of the Johnson & Johnson vaccine, it suggests that the vaccine may make an excellent booster for people who initially got two doses of an mRNA vaccine, experts said.